I aspire to identify stocks that can be purchased now and held for a year to achieve long term capital gains. I seek to identify stocks that will at least double in value. I encourage you to consider these stocks yet do your own research before investing.

$ABEO New Treatment Center - Presbyterian/Columbia University Irving Medical Center in New York, NY There are now 5 treatment centers. https://t.co/ZNrGSDRdua

$ABEO $RARE UX111 PDUFA Sep 19, 2026 $ABEO handed off UX111, a gene therapy for Sanfilippo syndrome, to Ultragenyx ($RARE) in exchange for royalties and milestone payments. It had been given a PDUFA action date of August 18, 2025. In July 2025, the FDA issued a CRL

$AQST Interpreting the Type A Meeting Results Aquestive Therapeutics issued this statement after the Type A meeting: "The Company and FDA aligned on the concept of including labeling language to manage potential chewing of the film rather than creating additional clinical

$FATE   Quiet Period Likely Ahead My guess is there will be no data updates until the mid-May quarterly or a conference like EULAR 2026 in early June. Yes, there is always the posibility of a surprise press release. Any hints that have been dropped seem to suggest no

$AQST Epi Preferences Study https://t.co/gkEXI3YJWb

$AQST Considering the Anaphylm TimeLine Meeting Minutes by Early May They likely want to have the meeting minutes in hand before going forward with the studies. FDA "meeting minutes" actually often include new clarification and recommendations. It sounds like a meeting

$AQST Anticipating Label Update Based on the press release today, I am expecting the addition of the words "do not chew" to the label directions. (I added the text in red below.)

$AQST Type A Meeting - Key Result "The Company and FDA aligned on the concept of including labeling language to manage potential chewing of the film rather than creating additional clinical data." -Final FDA meeting minutes expected by early May 2026 - Reaffirms guidance to

$IOVA APLB Letter I want the FDA to monitor false advertising. This just goes way too far. I find the data reported here about 5-year survival to be accurate. The footnote is clear this is a single-arm trial. Context Matters! The persons in this study have exhausted all

$COYA Response to Video I really appreciate this video. It combines an excellent interview by Brad Loncar with highly effective communication by Arun. There is nothing new here from Arun, yet it is important to keep telling the story of this small company to investors,

$AQST Neffy versus Anaphylm Instructions

$VKTX Enrollment Complete Phase 3 SC 78 weeks from today is: September 22, 2027. So, I am expecting early November data. ObesityWeek 2027 will be held November 8–11, 2027. All signals point to a big presentation of data there. https://t.co/N71X4mqBG2

$CRDF Looking Ahead to Late Summer Today's presentation was a reminder that with a July 22 cutoff of the data in this chart, it will shift from 12 months to 18 months post treatment. The control group had a PFS of 11 months. With a July cutoff, there will be an

$IBRX Clinical trial to use Anktiva and AgenT-797 iNKT OFF-the-shelf Cell Therapy for those in ICU with severe community-acquired Pneumonia There are no study locations listed, so it may be some time before the study starts. Setting up a contract with a hospital may take at